Commercial portfolio
Spinout companies at the University of Sheffield.
If you have any queries about the University's commercial portfolio, please contact commercialisationteam@sheffield.ac.uk
Aclipse Therapeutics
Aclipse Therapeutics is developing two novel and highly differentiated drug candidates as life-changing treatments for patients with severe diseases. M107 is the first potential disease-modifying drug for the treatment of gastroparesis and is preparing to enter its Phase 2 trial. M102 is the first potential targeted medicine for the treatment of sporadic motor neurone disease (MND or ALS) and is preparing to enter its Phase 1 trial. M102 is the subject of an ongoing collaboration between Aclipse and the Sheffield Institute for Translational Neuroscience at the University of Sheffield. Aclipse has licensed intellectual property on M102 from the University of Sheffield.
AegiQ Ltd
Aegiq is a full stack quantum computing and quantum networking company. It is on the mission to deliver the first commercially viable and universal multi-million qubit quantum computer enabled by quantum networking.
The company uses its unique hybrid integrated photonics approach to solve the million-qubit challenge and unlock economies of scale for quantum technology. Already offering a portfolio of products and solutions covering cybersecurity, quantum communications, quantum networking, quantum-enhanced sensing, and quantum computing, Aegiq helps global leaders in R&D, telecom, defence & aerospace, financial and advanced manufacturing sectors stay ahead of the tech curve.
Asterion Ltd
Asterion is generating and developing long-acting biopharmaceutical products that can be administered at a lower dose, less frequently and with fewer side effects than existing marketed drugs.
Read more: Commercial impact of a Sheffield spinout (Asterion Ltd)
BOW (Bettering Our Worlds through robotics)
A University-funded project that explores the power of robotics, and how it can be used to transform our lives.
Crucible Therapeutics
Crucible is a biotechnology company developing novel therapies to treat the most common genetic form of motor neurone disease (MND), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Diurnal Ltd
Diurnal is developing a novel approach to drug delivery that will help patients suffering from reduced levels of the key hormone cortisol (hydrocortisone).
Everybaby
Research carried out on Electrical Impedance Spectroscopy at the University has led to the creation of a new medical device that improves the accuracy of pre-term birth diagnosis.
Read more: Breakthrough medical device to improve prediction of preterm birth
Evolutor
Evolutor is a biotechnology company building vital infrastructure to produce market-leading microbial production hosts for the sustainable biomanufacture of chemicals, fuels, materials, food ingredients and beyond.
The company is developing proprietary technologies and molecular tools to fully harness the innate power of evolution for industrial use. Evolutor's ambition is to build the world's first massively parallelized evolutionary bio-foundry in Sheffield.
Farapack Polymers
Established in 2004, Farapack Polymers provides consultancy to a range of industries. The range of services provided includes polymer synthesis, analysis and mechanical testing.
FourJaw Manufacturing Analysis Ltd
FourJaw delivers accessible technology that empowers manufacturers to achieve their productivity potential. FourJaw is the industry's most accessible and affordable manufacturing analytics software platform.
Geoptic Ltd
Geoptic Infrastructure Investigations Limited is a spinout company from the collaboration of three UK universities with the founders’ expertise spanning geophysics, applied nuclear, and particle physics. Geoptic utilises highly-penetrating cosmic ray particles, known as muons, in a method similar to the use of x-rays in the medical industry. This method, known as muon tomography, exploits naturally-occurring radiation to image otherwise difficult to access objects in a non-invasive and non-destructive manner.
Geoptic has successfully applied their novel instrumentation and technique to infrastructure imaging as a means of identifying, locating, and characterising hidden voiding and shafts in the overburden of railway tunnels. This innovative technique is revolutionising remedial tunnel investigations across the UK rail network.
Keapstone Therapeutics Ltd
Keapstone is developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson’s and amyotrophic lateral sclerosis (ALS).
K-now Ltd
K-Now, a spinout from Computer Science, focuses primarily on social media and crowdsourcing methodologies for intelligence gathering and emergency management.
Visit the K-now Ltd LinkedIn page
LimitState Ltd
LimitState specializes in the development of powerful yet easy-to-use software applications which use unique technology to rapidly identify critical collapse mechanisms and associated margins of safety.
Magnomatics Ltd
Magnomatics is a high technology company that develops and manufactures products based on its proprietary groundbreaking magnetic gear technology.
Visit the Magnomatics Ltd website
Medella Therapeutics Ltd
Medella Therapeutics is focused on the discovery and development of novel drugs that interfere with the cell signalling activities of Receptor Activity Modifying Proteins or ‘RAMPs ’, which are implicated in diseases including cancer, inflammation, bone and cardiovascular disease.
Modulus Oncology Ltd
Since the incorporation of Modulus Oncology, the academic and commercialisation expert members of the company have undertaken a thorough and detailed ongoing review of our data package, seeking advice from external assessors. As a result, it has become clear that there are areas where additional strength is needed for maximum investor confidence. In order to obtain funding for those studies in the current economic climate we have together decided that the best way forward is to close down the company and return the IP to the University of Sheffield. This will allow continued and unencumbered applications for grant funding by the academic team, and we expect to resume formal commercialisation activities in due course.
We are still interested to explore development opportunities for our first-in-class oncology drug. Enquiries from interested parties may be addressed to Professor Tim Skerry (T.SkerryATSheffield.ac.uk) or Dr Sue Smith (sue.smithATsheffield.ac.uk) in the first instance.
Neuresta Inc
Neuresta is a biopharmaceutical company focused on developing new therapies for chronic pain. Chronic pain affects hundreds of millions of people worldwide. Despite the tremendous socioeconomic impact of chronic pain, few therapeutic options are currently available. Opioid drugs commonly used for pain management are addictive.
Neuresta is committed to addressing this global healthcare problem with science-based innovation. Our mission is to help those suffering from chronic pain by fulfilling the unmet need for effective, safe and non-addictive medications. Since chronic pain is usually localized, we develop local analgesics for strategic treatments of affected areas of the body. Our lead candidates are expected to offer long-lasting pain relief after a single injection without addiction or systemic side effects.
Opteran Technologies Ltd
Opteran is pioneering its radical lightweight, low-cost silicon-based approach to autonomy called Natural Intelligence.
They expect their technology will significantly expand the potential addressable market for autonomy in machines and robotics.
Visit the Opteran Technologies Ltd website
Productive Machines Ltd
Productive Machines uses an algorithm to optimise milling machine tool settings (spindle speeds and feed rates) using a digital twin developed in the Advanced Manufacturing Research Centre (AMRC). The technology is unique in the market in being able to identify high-performance stable characteristics and settings that boost manufacturing performance.
Perlemax Ltd
Perlemax technology enables the super-efficient generation of micro-sized bubbles of gas in a liquid, which can improve productivity and save energy across a wide spectrum of industrial processes.
Visit the Perlemax Ltd website
PH Therapeutics Ltd
PH Therapeutics is developing novel antibody therapies to treat the orphan disease Pulmonary Arterial Hypertension (PAH), a chronic condition with high levels of mortality.
Phase Focus Ltd
Phase Focus, the Sheffield-based microscopy company, raised £3.2m in equity-based funding round in June 2012 to accelerate revenue generation of its revolutionary nanotech imaging and microscopy technology – the Phase Focus Virtual Lens®.
Visit the Phase Focus Ltd website
Phlux Technologies Ltd
Phlux is building high performance infrared sensors for communications, LIDAR and sensing to enable a clean and connected future.
Plume Biotechnology
Plume Biotechnology is developing sustainable functional food solutions for the nutrition and beverage market. Our unique biotechnology platform converts industrial waste streams into highly nutritious plant based algal biomass without the need for complex lighting systems. Our novel IP enables us to generate high stability natural colours addressing specific market unmet needs, thus expanding the application space for natural colours in the growing food and beverage sector for our partners.
Our mission of improving consumer access to natural, nutritional food ingredients, while reducing raw material, water, energy and land use requirements inspires us to bring our differentiated, sustainable technology to market. We have demonstrated the scalable capabilities of our core technology. We now look to develop a food grade system in collaboration with our growing pipeline of global brand driven industrial partners.
Enquiries from interested parties may be addressed to CEO Dr Thomas Burns (t.burnsATplumebiotech.com)
PyrOptik Intruments Ltd
PyrOptik offers expert measurement application consultancy, system design and supply to customer specification. We do this by developing novel opto-electronic metrology solutions that survive in the harshest of applications from our team of design engineers which include optics, electronics, mechanics, software and metrology analysis specialists.
The company was founded to provide best in class non-contact optical measurement solutions addressing unmet or inadequately serviced measurement challenges in specific industrial and academic niches
PyrOptik believes in a research led approach to developing products working closely with end users to fully understand the benefits of data to improving the process being analysed. A key guiding philosophy for the company is we believe improved instrumentation and subsequent measurements will allow improved energy efficiency and consequently reduced carbon emissions.
Regenerative Cell Therapy Consulting (Regen CTC)
Regenerative Cell Therapy Consulting (Regen CTC) is a network of UK academic experts with real world experience of translating human pluripotent stem cell (hPSC)-derived cell therapies to the clinic.
Established under the UK Regenerative Medicine Platform in 2018, Regen CTC’s members include fundamental scientists, manufacturing engineers, clinicians and expert translational scientists with experience in developing quality management systems, clean room operations and process development of research protocols.
Our mission is to use our knowledge and experience to accelerate your cell and gene therapy developmental pipeline, helping you to avoid common pitfalls. In so doing, our translational consultants hope to be able to assist advanced therapy developers to deliver their complex therapies to the clinic so that the patients who need them can begin to see their benefits.
Rinri Therapeutics Ltd
Rinri Therapeutics is a biotechnology research and development company engaged in the product development of advanced therapies to treat hearing loss.
Zilico Ltd
Zilico’s Electrical Impedance Spectroscopy (EIS) technology is incorporated into ZedScan, a post-screening cervical cancer diagnostic system that is more accurate than incumbent techniques and provides real-time information to the clinician enabling better patient management at the first appointment.